Nucleotide-binding and oligomerization domain (NOD)-like receptors in teleost fish : Current knowledge and future perspectives

© 2018 John Wiley & Sons Ltd.

Détails bibliographiques
Publié dans:Journal of fish diseases. - 1998. - 41(2018), 9 vom: 10. Sept., Seite 1317-1330
Auteur principal: Zhang, Liang (Auteur)
Autres auteurs: Gao, Zhuying, Yu, Li, Zhang, Bo, Wang, Jing, Zhou, Jun
Format: Article en ligne
Langue:English
Publié: 2018
Accès à la collection:Journal of fish diseases
Sujets:Journal Article Review Nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) innate immune system pathogen/pattern-recognition receptors (PRRs) teleost fish Fish Proteins Lipopolysaccharides NLR Proteins Receptors, Pattern Recognition plus... Poly I-C O84C90HH2L
Description
Résumé:© 2018 John Wiley & Sons Ltd.
Nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) are a group of intracellular pathogen recognition receptors (PRRs) that play key roles in pathogen recognition and subsequent activation of innate immune signalling pathways. Expressions of several NLR subfamily members, including NOD1, NOD2, NLR-C3, NLR-C5 and NLR-X1 have been reported in many different teleost fish species. These receptors are activated by a variety of ligands, including lipopolysaccharides (LPS), peptidoglycans (PGN) and polyinosinic-polycytidylic acid [Poly(I:C)]. Synthetic dsRNA and bacterial or viral infections are known to stimulate these receptors both in vitro and in vivo. In this review, we focus on the identification, expression and function of teleost NLRs in response to bacterial or viral pathogens. Additionally, NLR ligand specificity and signalling pathways involved in the recognition of bacterial or viral stimuli are also summarized. This review focuses on current knowledge in this area and provides future perspectives regarding topics in need of additional investigation. Understanding the response of innate immune system to bacterial or viral infections in diverse species could inform the development of more effective therapies and vaccines
Description:Date Completed 30.01.2019
Date Revised 30.09.2020
published: Print-Electronic
GENBANK: KC207831.1, NM_001328044.1, JQ073815.1, XM_680389.9, FJ004844.1, FJ004845.1, FJ004846.1, FJ004847.1, FJ004848.1, KR921862.1, KR921863.1, KR921864.1, KF484402.1, HM133906.1, HM133907.1, KX449137.1, KX449138.1, KX449139.1, FJ937972.1, FJ937973.1, JX220894.1, JX220895.1, JX965184.1, JX965185.1, KT354221.1, JX965186.1, XM_005472372.3, XM_003437543.4, XM_003438603.4, JF830014.1, KP347441, LC158841.1, JN794079.1, JF923468.1, KC113242.1, KC113243.1, KC542884.1, KT826538.1, KX611691.1, KY437762.1, KY437763.1, XM_014149024.1
Citation Status MEDLINE
ISSN:1365-2761
DOI:10.1111/jfd.12841